SCHEMBL24933795

SCHEMBL24933795

NC(=O)c1cc(-c2ccc(OCc3cnc(OC4CCCC4)nc3)cc2)c(C(F)(F)F)[nH]c1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 2/20 0.35
MKNK2 Q9HBH9 2/20 0.35
FFAR4 Q5NUL3 2/20 0.34
HDAC3 O15379 1/20 0.34
PARP1 P09874 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC10 Q969S8 1/20 0.34
HDAC11 Q96DB2 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
HDAC9 Q9UKV0 1/20 0.34
HDAC5 Q9UQL6 1/20 0.34
NEK2 P51955 3/20 0.34
MAOB P27338 3/20 0.33
PRMT5 O14744 1/20 0.33
CHEK2 O96017 1/20 0.33
PDE4A P27815 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24933228 0.90 CYP11B1 (0.37) HDAC3PARP1HDAC4HDAC1HDAC7
SCHEMBL24933810 0.87 FFAR4 (0.40) FFAR4HDAC3PARP1HDAC4HDAC1
SCHEMBL24933227 0.86 BRS3 (0.37) HDAC3PARP1HDAC4HDAC1HDAC7
SCHEMBL24933213 0.86 MAOB (0.36) HDAC3PARP1HDAC4HDAC1HDAC7
SCHEMBL24933812 0.86 SYK (0.39) SYK
SCHEMBL24933385 0.85 PARP1 (0.39) HDAC3PARP1HDAC4HDAC1HDAC7
SCHEMBL24933814 0.84 PRKAB2 (0.38) HDAC3PARP1HDAC4HDAC1HDAC7
SCHEMBL24932987 0.84 SYK (0.40) PARP1MAOBHSD17B1HSD17B2SYK
SCHEMBL24933441 0.83 MAPK8 (0.38) HDAC3PARP1HDAC4HDAC1HDAC7
SCHEMBL30240713 0.83 CCR6 (0.40) MAOBPRMT5SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP claimed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN claimed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO claimed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed